Exelixis, Inc. (NASDAQ:EXEL) Position Trimmed by Vinva Investment Management Ltd

Vinva Investment Management Ltd lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 10.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,051 shares of the biotechnology company’s stock after selling 2,536 shares during the quarter. Vinva Investment Management Ltd’s holdings in Exelixis were worth $701,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. FMR LLC lifted its holdings in shares of Exelixis by 6.1% during the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after buying an additional 140,568 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in shares of Exelixis by 20.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company’s stock valued at $71,828,000 after buying an additional 366,141 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Exelixis by 6.1% during the 3rd quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company’s stock valued at $44,182,000 after buying an additional 98,000 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after buying an additional 704,786 shares during the last quarter. Finally, Systematic Financial Management LP lifted its holdings in shares of Exelixis by 7.1% during the 3rd quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company’s stock valued at $30,320,000 after buying an additional 77,599 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares in the company, valued at $28,174,996.98. This represents a 3.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now owns 341,028 shares of the company’s stock, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Truist Financial boosted their target price on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Citigroup boosted their target price on Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 19th. Guggenheim restated a “buy” rating and issued a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Exelixis in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Trading Down 0.6 %

NASDAQ:EXEL opened at $36.96 on Friday. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02. The business’s 50-day moving average price is $35.61 and its two-hundred day moving average price is $32.82. The firm has a market capitalization of $10.34 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Sell-side analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.